ABHD6 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ABHD6 gene in SK-HEP-1 human hepatic adenocarcinoma cells. This product provides a genetically heterogeneous pool of gene-edited cells, generated by CRISPR/Cas9-mediated target-gene disruption, enabling loss-of-function studies without clonal isolation. The polyclonal format captures diverse editing outcomes across the population, offering a robust model for investigating ABHD6-dependent phenotypes in endocannabinoid-related signaling and lipid metabolism.
The host cell line, SK-HEP-1, was originally established from the ascites of a patient with liver adenocarcinoma. It is widely employed in hepatocellular carcinoma research, drug metabolism studies, and as a model of endothelium-like properties. SK-HEP-1 cells exhibit a mixed epithelial and mesenchymal phenotype, making them particularly useful for interrogating tumor biology, metastatic behavior, and metabolic signaling in a hepatic cancer context.
ABHD6 encodes a monoacylglycerol lipase that selectively hydrolyzes 2-arachidonoylglycerol (2-AG) into arachidonic acid and glycerol, thereby limiting endocannabinoid tone at cannabinoid receptors CB1 and CB2. Disruption of ABHD6 elevates 2-AG levels, leading to amplified CB1/CB2 receptor activity and downstream modulation of MAPK and PI3K/Akt signaling cascades. This gene is transcriptionally regulated by PPAR?? and PPAR??, and its activity influences arachidonic acid flux, eicosanoid synthesis, and metabolic crosstalk. ABHD6 functions in coordination with other lipases such as DAGL, MAGL, and ABHD12, positioning it within a broader network controlling lipid mediator bioavailability.
In the SK-HEP-1 background, ABHD6 knockout is expected to shift endocannabinoid signaling toward a pro-migratory and proliferative state via sustained 2-AG-dependent CB1/CB2 activation. Elevated 2-AG may also feed into eicosanoid pathways, fostering an inflammatory microenvironment relevant to hepatocellular carcinoma progression. This model thus permits dissection of how monoacylglycerol lipase activity intersects with tumor cell metabolism, lipid droplet dynamics, and oncogenic signaling through MAPK and PI3K/Akt axes, while preserving the intrinsic heterogeneity of polyclonal populations.
This polyclonal knockout cell population supports a wide array of applications in academic and pharmaceutical research. It is suitable for endocannabinoid signaling studies, liver cancer metabolism research, drug target validation, and metabolic disease modeling. Researchers can employ standard assays such as Western blotting and RT-qPCR to confirm ABHD6 loss, LC-MS/MS for 2-AG quantification, and functional assays addressing cell proliferation (MTS/MTT), migration (wound healing/Transwell), apoptosis (Annexin V), lipid droplet staining, and inflammatory marker analysis (TNF-?? ELISA). For further information or to discuss custom projects, please contact Ascent Research.
